Details of the Drug

General Information of Drug (ID: DMAH70G)

Drug Name
Molindone
Synonyms
Molindona; Molindonum; Molindone Monohydrochloride; Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 276.37
Logarithm of the Partition Coefficient (xlogp) 1.7
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Elimination
2% of drug is excreted from urine in the unchanged form [2]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.63 micromolar/kg/day [3]
Chemical Identifiers
Formula
C16H24N2O2
IUPAC Name
3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one
Canonical SMILES
CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
InChI
InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
InChIKey
KLPWJLBORRMFGK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
23897
ChEBI ID
CHEBI:6965
CAS Number
7416-34-4
DrugBank ID
DB01618
TTD ID
D09TPF
ACDINA ID
D00444

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Binder [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Molindone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Molindone and Iloperidone. Schizophrenia [6A20] [5]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Molindone and Thiothixene. Schizophrenia [6A20] [5]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Molindone and Asenapine. Schizophrenia [6A20] [5]
Coadministration of a Drug Treating the Disease Different from Molindone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Molindone and Oliceridine. Acute pain [MG31] [6]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Molindone and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Molindone and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Molindone and Cariprazine. Bipolar disorder [6A60] [5]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Molindone when combined with Acetylcholine. Cataract [9B10] [8]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Molindone and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [9]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Molindone and Revefenacin. Chronic obstructive pulmonary disease [CA22] [9]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Molindone and Cyclandelate. Dementia [6D80-6D8Z] [10]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Molindone and OPC-34712. Depression [6A70-6A7Z] [5]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Molindone and Esketamine. Depression [6A70-6A7Z] [11]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Molindone and Mepenzolate. Digestive system disease [DE2Z] [5]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Molindone and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [12]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Molindone and Deutetrabenazine. Dystonic disorder [8A02] [13]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Molindone and Nebivolol. Hypertension [BA00-BA04] [10]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Molindone and Levamlodipine. Hypertension [BA00-BA04] [10]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Molindone and TAK-491. Hypertension [BA00-BA04] [10]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Molindone and Clevidipine butyrate. Hypertension [BA00-BA04] [10]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Molindone and Belladonna. Infectious gastroenteritis/colitis [1A40] [5]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Molindone and ITI-007. Insomnia [7A00-7A0Z] [5]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Molindone and Polyethylene glycol. Irritable bowel syndrome [DD91] [14]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Molindone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [15]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Molindone and Lasmiditan. Migraine [8A80] [16]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Molindone and Flibanserin. Mood disorder [6A60-6E23] [17]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Molindone and Phenindamine. Nasopharyngitis [CA00] [5]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Molindone and Lorcaserin. Obesity [5B80-5B81] [18]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Molindone and Lofexidine. Opioid use disorder [6C43] [10]
Opicapone DM1BKA6 Moderate Additive hypotensive effects by the combination of Molindone and Opicapone. Parkinsonism [8A00] [19]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Molindone and Methylscopolamine. Peptic ulcer [DA61] [5]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Molindone and Silodosin. Prostate hyperplasia [GA90] [10]
Neupro DMHEAB1 Moderate Antagonize the effect of Molindone when combined with Neupro. Restless legs syndrome [7A80] [19]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Molindone and Acrivastine. Vasomotor/allergic rhinitis [CA08] [5]
⏷ Show the Full List of 31 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Molindone 25 mg tablet 25 mg Oral Tablet Oral
Molindone 10 mg tablet 10 mg Oral Tablet Oral
Molindone 5 mg tablet 5 mg Oral Tablet Oral
Molindone Hydrochloride 25mg tablet 25mg Tablet Oral
Molindone Hydrochloride 10mg tablet 10mg Tablet Oral
Molindone Hydrochloride 5mg tablet 5mg Tablet Oral
Molindone Hydrochloride 50mg tablet 50mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 207).
2 BDDCS applied to over 900 drugs
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083.
5 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
6 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
7 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
8 Multum Information Services, Inc. Expert Review Panel.
9 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
10 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
11 Cerner Multum, Inc. "Australian Product Information.".
12 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
13 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
14 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
15 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
16 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
17 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
18 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
19 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]